Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Boryung Blasts Into Space
Executive Summary
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
You may also be interested in...
Korea's New Fast Track Scheme A GIFT For High-Need Drugs
South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.
What's Keeping Korea From Adopting Decentralized Clinical Trials?
The current status of decentralized clinical trials in Korea and the country’s efforts to boost activity in this area were discussed at the recent Bio Korea meeting, with cultural and medical practices, along with technological and medical literacy, among the areas seen as affecting broader adoption of the various elements of the approach.